Epigenetics, an increasingly popular field of drug discovery, is the study of heritable changes in gene expression that occur without changes in the DNA sequence. The epigenome is considered to be in constant flux and is responsive to environmental and pharmaceutically active molecules. Epigenetics-related enzymes and proteins catalyze the addition or removal of an array of covalent modifications on histone and non-histone proteins. For these reasons, epigenetics is becoming an increasingly important realm for drug therapies. Indeed, several drugs directed towards epigenetic modifying enzymes are already on the market with more in the clinic focused on cancer.
Eurofins Discovery offers an epigenetic service that utilizes several technology platforms and allows for your choice of technology and/or substrates, providing added flexibility to meet your drug discovery needs.
Better Understand your epigenetics drug discovery programs.
Key Areas
BROMOscan Technology
Based on the proven KINOMEscan™ technology, BROMOscan is a novel bromodomain inhibitor binding platform that measures the interactions between test compounds and a panel of bromodomain assays.
Episcan-Cell Based Assays for Incell Hunter
EPIscan screening and profiling services provides a rapidly growing menu of cell-based bromodomain and histone methyltransferase (HMT) assays.
Features
Features
Questions? Contact Us
You can easily get in touch with a Eurofins Discovery Expert or get help from our Customer Service team. Reach out with questions, or to discuss your specific discovery challenges.
